Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P31751

UPID:
AKT2_HUMAN

ALTERNATIVE NAMES:
Protein kinase Akt-2; Protein kinase B beta; RAC-PK-beta

ALTERNATIVE UPACC:
P31751; B2RBD8; Q05BV0; Q0VAN0; Q0VAN1; Q68GC0

BACKGROUND:
AKT2, a key enzyme in the AKT kinase family, orchestrates a wide array of cellular functions by phosphorylating downstream substrates. This includes the regulation of glucose transport, cell proliferation, and survival mechanisms, highlighting its central role in maintaining cellular homeostasis and response to insulin.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of RAC-beta serine/threonine-protein kinase could open doors to potential therapeutic strategies. Its involvement in Type 2 diabetes mellitus and Hypoinsulinemic hypoglycemia underscores the therapeutic potential of modulating AKT2's activity to manage these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.